What recent moves in Veradermics (MANE) might be telling you
Veradermics (MANE) has drawn attention after a sharp month return of about 72% and a very large past 3 months move, putting its clinical stage dermatology pipeline and valuation in sharper focus for investors.
See our latest analysis for Veradermics.
The recent 72% 30 day share price return and very large 90 day move sit alongside a 190.78% year to date share price return, which points to strong upward momentum despite a 4.38% one day pullback to US$109.77.
If you are looking beyond Veradermics for other healthcare opportunities using AI or data driven approaches, now is a good time to scan 32 healthcare AI stocks
With Veradermics still loss making, trading around US$109.77 and sitting at roughly a 15% discount to a published US$126 price target despite a strong year to date run, is this a fresh entry point, or is the market already pricing in future growth?
DCF suggests a large valuation gap: is it justified?
The SWS DCF model estimates a fair value of about $382.79 per share for Veradermics, compared with the latest close at $109.77, implying a large discount based on those cash flow assumptions.
The DCF approach projects a stream of future cash flows and discounts them back to today using a required rate of return. This produces a single present value estimate. For a clinical stage biopharmaceutical company with no current revenue and a loss of $83.373m, this type of model depends heavily on assumptions around eventual commercialisation, margins and funding needs.
Veradermics is still loss making, reports no revenue and is forecast to remain unprofitable over the next 3 years. Yet the SWS DCF model still arrives at a figure more than three times the current share price. That gap reflects the degree to which long term expectations for its dermatology pipeline differ from what is currently being priced in, rather than anything observable in today’s income statement.
Look into how the SWS DCF model arrives at its fair value.
Result: DCF Fair value of $382.79 (UNDERVALUED)
However, there are clear risks, including clinical trial setbacks across multiple programs and the need to fund operations while Veradermics reports no revenue and a US$83.373m loss.
Find out about the key risks to this Veradermics narrative.
Next Steps
With sentiment clearly mixed, it is worth reviewing the underlying data yourself and deciding how much risk and potential upside you are comfortable with before acting. To consider these trade offs in one place, start with the 1 key reward and 3 important warning signs
Looking for more investment ideas?
If you stop at just one stock, you risk missing other opportunities that could fit your goals just as well, or even better.
- Spot potential turnaround stories early by scanning 24 elite penny stocks with strong financials that already show stronger financial footing than many tiny peers.
- Focus your energy on quality by filtering for companies in solid balance sheet and fundamentals stocks screener (45 results) that pair healthier finances with meaningful business fundamentals.
- Hunt for future standouts with screener containing 23 high quality undiscovered gems that may not be widely followed yet, but already have the numbers to back them up.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com